Apr 19, 2023 / 06:15PM GMT
David Saxon - Needham & Company - Analyst
Hi. Good afternoon, and thank you for joining us at the 22nd Annual Needham Healthcare Conference. My name is David Saxon. I'm one of the analysts on the medtech equity research team here at Needham & Company. With me today is the RxSight team, including President and CEO, Dr. Ron Kurtz; and CFO, Shelly Thunen.
Instead of a standard presentation, we're going to do a Q&A session. If you do have any questions that you'd like to ask, you can submit them electronically through the Needham conference website or you can feel free to e-mail them to me at [email protected], and I'll do my best to fit them in.
Questions and Answers:
David Saxon - Needham & Company - AnalystSo with that, I guess we'll jump into the Q&A. Maybe to start, I wanted to see if you could talk about the procedure volume trends you're seeing during the first quarter and maybe remind us what's assumed in guidance.
Shelley Thunen - RxSight, Inc. - Assistant Secretary and CFO
Trustpilot
